Status:
COMPLETED
Optimizing Prograf® Therapy in Renal Transplant Patients
Lead Sponsor:
Astellas Pharma Inc
Collaborating Sponsors:
Astellas Pharma US, Inc.
Conditions:
Renal Transplantation
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
A study to determine the optimal dose and blood level of Prograf® in long-term maintenance of kidney transplant patients.
Detailed Description
A 3 arm study (2 Active, 1 Active Control) to determine the optimal dose and blood level of Prograf® in long-term maintenance of kidney transplant patients
Eligibility Criteria
Inclusion
- Patient was 18 years of age at the time of transplant.
- Patient is at least 6 months post-transplant.
Exclusion
- Patient is the recipient of a solid organ transplant other than the kidney.
- Patient is a known carrier of any of the HIV viruses.
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2006
Estimated Enrollment :
323 Patients enrolled
Trial Details
Trial ID
NCT00297765
Start Date
January 1 2003
End Date
March 1 2006
Last Update
August 26 2008
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States, 35294
2
Little Rock, Arkansas, United States, 72205
3
Los Angeles, California, United States, 90057
4
Palo Alto, California, United States, 94304